K. Belhadj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
K. Belhadj has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Corinne Haioun
Lymphoid Malignancies Unit, AP-HP, Groupe Hospitalier Mondor, Créteil, France
5 shared publications - Alain Rahmouni
Imagerie médicale, hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil cedex, France
3 shared publications F. Reyes
Hôpital Henri Mondor, Créteil, France
3 shared publicationsI. Gaillard
3 shared publicationsJ. Dupuis
3 shared publicationsA. Allain
Hôpital Henri Mondor, Créteil, France; Sanofi-Synthelabo, Paris, France
2 shared publications
Latest Publications
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 8150
Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging.
8150 Background: Patients (pts) with multiple myeloma (MM) have higher microvessel density (MD) than control subjects. Bone marrow MD of responders decreases after therapy. Microcirculatory parameters of dynamic contrast-enhanced MR imaging correlate well with histologic grade of infiltration, MD, and serum markers of MM activity. A reduction in these parameters has been observed in pts who respond to treatment. Methods: To compare posttreatment bone marrow changes at dynamic whole-body contrast-enhanced MR (dWBMR) imaging with clinical response in pts with MM and to determine if dWBMR can be used to assess treatment response. 30 pts, median age 58 years, underwent dWBMR imaging before treatment, after induction chemotherapy and after autologous stem cell transplantation (ASCT) (n = 20). Maximal percentages of bone marrow (BME max) and focal lesion (FLE max) enhancement were assessed at each dWBMR imaging examination. Clinical responses were determined on the basis of IMWG uniform response criteria. Post treatment changes in BME max and FLE max were compared with clinical response. Receiver operating characteristic (ROC) analysis of post treatment BME max was used to identify poor responders. Results: 11 of 30 pts were good responders to induction; 16 of 20 pts were good responders to ASCT. After induction chemotherapy, mean BME max differed (p = .02) between good (94.3%) and poor responders (138.4%). A post treatment BME max of more than 96.8% had 100% sensitivity for the identification of poor responders (specificity, 76.9%; area under the ROC curve, 0.90; p = .0001). Mean FLE max after induction chemotherapy did not differ between good and poor responders. Mean timing (number of post contrast dynamic acquisitions where FLE max was observed) was delayed in good responders compared with poor responders (4.7 vs 2.9 minutes, p = .0001). Post-ASCT dWBMR imaging results correctly depicted all four clinically good responders whose disease subsequently progressed (2 to 15 months). Conclusions: With quantitative analysis of BME max and the timing of FLE max, dWBMR imaging can be used to assess treatment response in pts with MM. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 8150
Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging.
8150 Background: Patients (pts) with multiple myeloma (MM) have higher microvessel density (MD) than control subjects. Bone marrow MD of responders decreases after therapy. Microcirculatory parameters of dynamic contrast-enhanced MR imaging correlate well with histologic grade of infiltration, MD, and serum markers of MM activity. A reduction in these parameters has been observed in pts who respond to treatment. Methods: To compare posttreatment bone marrow changes at dynamic whole-body contrast-enhanced MR (dWBMR) imaging with clinical response in pts with MM and to determine if dWBMR can be used to assess treatment response. 30 pts, median age 58 years, underwent dWBMR imaging before treatment, after induction chemotherapy and after autologous stem cell transplantation (ASCT) (n = 20). Maximal percentages of bone marrow (BME max) and focal lesion (FLE max) enhancement were assessed at each dWBMR imaging examination. Clinical responses were determined on the basis of IMWG uniform response criteria. Post treatment changes in BME max and FLE max were compared with clinical response. Receiver operating characteristic (ROC) analysis of post treatment BME max was used to identify poor responders. Results: 11 of 30 pts were good responders to induction; 16 of 20 pts were good responders to ASCT. After induction chemotherapy, mean BME max differed (p = .02) between good (94.3%) and poor responders (138.4%). A post treatment BME max of more than 96.8% had 100% sensitivity for the identification of poor responders (specificity, 76.9%; area under the ROC curve, 0.90; p = .0001). Mean FLE max after induction chemotherapy did not differ between good and poor responders. Mean timing (number of post contrast dynamic acquisitions where FLE max was observed) was delayed in good responders compared with poor responders (4.7 vs 2.9 minutes, p = .0001). Post-ASCT dWBMR imaging results correctly depicted all four clinically good responders whose disease subsequently progressed (2 to 15 months). Conclusions: With quantitative analysis of BME max and the timing of FLE max, dWBMR imaging can be used to assess treatment response in pts with MM. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 8089
Clinical relevance of a positive result in cerebrospinal fluid (CSF) by flow cytometry (FCM) in patients with diffuse large B-cell lymphoma (DLBCL).
8089 Background: Central nervous system (CNS) relapse is an uncommon but serious complication of non-Hodgkin lymphoma and usually occurs early in the disease course, suggesting subclinical disease at diagnosis. Several studies have demonstrated the superiority of FCM analysis of CSF, as compared to conventional cytology (CC), in detecting occult leptomeningeal disease in heterogeneous groups of aggressive lymphoma. Nevertheless, the clinical relevance of a positive FCM is still to be determined in DLBCL. Methods: We reviewed CSF samples from 114 patients (pts) with DLBCL (15% being transformed follicular lymphoma), analyzed both by FCM and CC, between 2005 and 2009. Ninety-three samples were from newly diagnosed (ND) pts and 21 from pts in relapse. The R-IPI in ND was very good (2%), good (42%) and poor (56%). First-line treatments included R-CHOP (n=81) and R- ACVBP (n=9) regimens with methotrexate intrathecal prophylaxis, and pts in relapse received several types of salvage treatments. A FCM+ did not influence treatment strategies. Results: Seventeen samples of the 114 were FCM+, versus 1 sample CC+ (this being also FCM+). In order not to overestimate the risk of CNS relapse, we excluded from the analysis pts with signs at presentation suggesting leptomeningeal disease (n=13). Therefore, within ND pts without neurological signs (n=86), 9 (10%) were FCM+, versus 4 FCM+ (27%) in the 15 pts in relapse. In the first group, 1/9 (11%) developed CNS relapse versus 0/4 (0%) in the second group. Within all pts without neurological signs (n=101), 4 (4%) relapsed in the CNS, with a median time to relapse of 5.2 months. In those, only 1/4 (25%) was FCM+ prior to relapse. Clinical features that showed an association with CNS relapse were: more than one extranodal site (ENS) of disease and the conjunction of elevated LDH and ENS>1 (p=0.04 and p=0.018, respectively). Conclusions: FCM gives far more positive results than CC, when analyzing CSF of pts with DLBCL (17/114 FCM+, versus 1/114 CC+). However, a positive FCM result did not translate into an increased relapse rate in the CNS, in this population. Therefore, FCM failed to have a predictive value in the occurrence of CNS relapse in DLBCL. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 8089
Clinical relevance of a positive result in cerebrospinal fluid (CSF) by flow cytometry (FCM) in patients with diffuse large B-cell lymphoma (DLBCL).
8089 Background: Central nervous system (CNS) relapse is an uncommon but serious complication of non-Hodgkin lymphoma and usually occurs early in the disease course, suggesting subclinical disease at diagnosis. Several studies have demonstrated the superiority of FCM analysis of CSF, as compared to conventional cytology (CC), in detecting occult leptomeningeal disease in heterogeneous groups of aggressive lymphoma. Nevertheless, the clinical relevance of a positive FCM is still to be determined in DLBCL. Methods: We reviewed CSF samples from 114 patients (pts) with DLBCL (15% being transformed follicular lymphoma), analyzed both by FCM and CC, between 2005 and 2009. Ninety-three samples were from newly diagnosed (ND) pts and 21 from pts in relapse. The R-IPI in ND was very good (2%), good (42%) and poor (56%). First-line treatments included R-CHOP (n=81) and R- ACVBP (n=9) regimens with methotrexate intrathecal prophylaxis, and pts in relapse received several types of salvage treatments. A FCM+ did not influence treatment strategies. Results: Seventeen samples of the 114 were FCM+, versus 1 sample CC+ (this being also FCM+). In order not to overestimate the risk of CNS relapse, we excluded from the analysis pts with signs at presentation suggesting leptomeningeal disease (n=13). Therefore, within ND pts without neurological signs (n=86), 9 (10%) were FCM+, versus 4 FCM+ (27%) in the 15 pts in relapse. In the first group, 1/9 (11%) developed CNS relapse versus 0/4 (0%) in the second group. Within all pts without neurological signs (n=101), 4 (4%) relapsed in the CNS, with a median time to relapse of 5.2 months. In those, only 1/4 (25%) was FCM+ prior to relapse. Clinical features that showed an association with CNS relapse were: more than one extranodal site (ENS) of disease and the conjunction of elevated LDH and ENS>1 (p=0.04 and p=0.018, respectively). Conclusions: FCM gives far more positive results than CC, when analyzing CSF of pts with DLBCL (17/114 FCM+, versus 1/114 CC+). However, a positive FCM result did not translate into an increased relapse rate in the CNS, in this population. Therefore, FCM failed to have a predictive value in the occurrence of CNS relapse in DLBCL. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 6592
Rituximab, gemcitabine and oxaliplatin (R-GEMOX): A promising regimen for refractory/relapsed B-cell lymphoma
6592 Background: High-dose therapy with autologous stem cell support (HDT) is now an established treatment for chemosensitive relapse in aggressive lymphoma. However, not all patients are candidates for HDT because of age, comorbidities or previous HDT. Effective and well-tolerated salvage therapies with minimal toxicities are needed. Methods: We designed the R-GEMOX regimen, with rituximab 375mg/m2 d1, gemcitabine 1000 mg/m2 d2 and oxaliplatin 100 mg/m2 d2 (recycling on d15). Between January 2002 and August 2003, 24 patients with refractory/relapsing B-cell lymphoma not eligible for HDT were enrolled in an open unicenter pilot study whose primary objective was to determine the overall response rate (ORR) after 4 cycles of R-GEMOX. Patients were planned to receive 8 cycles if a good response (at least PR) was observed after 4 cycles. Median age was 64 years (range: 43–77) and histological subtypes were : diffuse large B-cell lymphoma (n=16), follicular (n=6) and mantle cell (n=2). Prior treatment included anthracyclin (n=22), rituximab (n=11) and HDT (n=6). The median number of prior treatments was 2 (range : 1 to 5) and 8 patients had received at least 3 prior regimens. Results: 172 cycles were given. The dose administered was 100% of the intended dose for the three drugs in all patients but 4, for whom the dose of oxaliplatin was reduced due to neurotoxicity (n=3) or preexisting renal insufficiency (n=1). Two patients progressed after 3 cycles. After 4 cycles, observed responses were: 6 CR, 4 CRu, 11 PR and 1 failure resulting in an ORR of 88 %. Among the 21 responders after 4 cycles, 17 achieved CR or CRu, 2 remained in PR after completion of 8 cycles. Treatment was stopped after 5 cycles in 2 patients because of physician decision. As of December 2003, 22 patients are alive, 15 in continuous complete remission, 3 in CRu, 2 in PR and 2 in progression. NCIC grade 3–4 neutropenia and thrombocytopenia were reported in 50% and 21% of cycles. Two patients developed a grade 4 infection. There was no renal toxicity. Conclusion: The R-GEMOX regimen shows promising activity with an acceptable toxicity. It is evaluated in an ongoing multicentric phase II study.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 6592
Rituximab, gemcitabine and oxaliplatin (R-GEMOX): A promising regimen for refractory/relapsed B-cell lymphoma
6592 Background: High-dose therapy with autologous stem cell support (HDT) is now an established treatment for chemosensitive relapse in aggressive lymphoma. However, not all patients are candidates for HDT because of age, comorbidities or previous HDT. Effective and well-tolerated salvage therapies with minimal toxicities are needed. Methods: We designed the R-GEMOX regimen, with rituximab 375mg/m2 d1, gemcitabine 1000 mg/m2 d2 and oxaliplatin 100 mg/m2 d2 (recycling on d15). Between January 2002 and August 2003, 24 patients with refractory/relapsing B-cell lymphoma not eligible for HDT were enrolled in an open unicenter pilot study whose primary objective was to determine the overall response rate (ORR) after 4 cycles of R-GEMOX. Patients were planned to receive 8 cycles if a good response (at least PR) was observed after 4 cycles. Median age was 64 years (range: 43–77) and histological subtypes were : diffuse large B-cell lymphoma (n=16), follicular (n=6) and mantle cell (n=2). Prior treatment included anthracyclin (n=22), rituximab (n=11) and HDT (n=6). The median number of prior treatments was 2 (range : 1 to 5) and 8 patients had received at least 3 prior regimens. Results: 172 cycles were given. The dose administered was 100% of the intended dose for the three drugs in all patients but 4, for whom the dose of oxaliplatin was reduced due to neurotoxicity (n=3) or preexisting renal insufficiency (n=1). Two patients progressed after 3 cycles. After 4 cycles, observed responses were: 6 CR, 4 CRu, 11 PR and 1 failure resulting in an ORR of 88 %. Among the 21 responders after 4 cycles, 17 achieved CR or CRu, 2 remained in PR after completion of 8 cycles. Treatment was stopped after 5 cycles in 2 patients because of physician decision. As of December 2003, 22 patients are alive, 15 in continuous complete remission, 3 in CRu, 2 in PR and 2 in progression. NCIC grade 3–4 neutropenia and thrombocytopenia were reported in 50% and 21% of cycles. Two patients developed a grade 4 infection. There was no renal toxicity. Conclusion: The R-GEMOX regimen shows promising activity with an acceptable toxicity. It is evaluated in an ongoing multicentric phase II study.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 6694
Rituximab in combination with CHOP regimen in T-cell angioimmunoblastic lymphoma (AILD-TL) rich in large B cells. Favourable results in four patients
6694 Background: B-cell clonal population is detected in 20% to 40% of AILD-TL. Moreover a subgroup of AILD-TL has been shown to display substantial number of CD20+ large B cells. This subgroup shares the poor prognosis of the classical AILD-TL with a 2-year survival of 40% (Lome-Maldonado, Leukemia 2002). We had postulated that this AILD-TL subgroup might benefit from a treatment with anti-CD20 monoclonal antibody (rituximab) combined to the classical CHOP regimen. Methods: We report four cases of untreated AILD-TL rich in large B cells treated with rituximab (375mg/m2 given on day 1 of each cycle) in combination with CHOP (cyclophosphamide, doxorubicine, vincristine, prednisone) chemotherapy (recycling at d21). Patients were planned to receive 8 cycles, if a good response (at least partial response) was observed after 4 cycles. Results: All the patients presented classical characteristics of AILD-TL with generalized lymphadenopathy, poor performance status, elevated LDH. 2 out of 4 patients had a serum M- component. Auto-immune hemolytic anemia occurred in 2 out of 4 patients. Histologic examinations revealed classical features of AILD-TL with more than 25% of large CD20+ cells with LMP-1 positivity in 2 cases. PCR analysis of tumoral lymph node showed a dominant T-cell clone in 2 cases, one of them also with a dominant B-cell clone. The two remaining cases had oligoclonal T-cell populations with polyclonal B-cell repertoire. A complete remission was achieved in 4 cases after 4 cycles and at the end of treatment for the 3 evaluable patients (treatment is still ongoing in one patient). One patient relapsed at 13 months with a low tumor burden and was treated with cyclophosphamide alone. At the present time, all the patients are alive without evolutive disease at 3, 20, 27 and 34 months. Conclusions : These results led us to consider that rituximab adjonction to CHOP could improve the prognosis of AILD-TL rich in large B cells. This combination warrants further evaluation in a larger phase II study. No significant financial relationships to disclose.
- 15 July 2004
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 6694
Rituximab in combination with CHOP regimen in T-cell angioimmunoblastic lymphoma (AILD-TL) rich in large B cells. Favourable results in four patients
6694 Background: B-cell clonal population is detected in 20% to 40% of AILD-TL. Moreover a subgroup of AILD-TL has been shown to display substantial number of CD20+ large B cells. This subgroup shares the poor prognosis of the classical AILD-TL with a 2-year survival of 40% (Lome-Maldonado, Leukemia 2002). We had postulated that this AILD-TL subgroup might benefit from a treatment with anti-CD20 monoclonal antibody (rituximab) combined to the classical CHOP regimen. Methods: We report four cases of untreated AILD-TL rich in large B cells treated with rituximab (375mg/m2 given on day 1 of each cycle) in combination with CHOP (cyclophosphamide, doxorubicine, vincristine, prednisone) chemotherapy (recycling at d21). Patients were planned to receive 8 cycles, if a good response (at least partial response) was observed after 4 cycles. Results: All the patients presented classical characteristics of AILD-TL with generalized lymphadenopathy, poor performance status, elevated LDH. 2 out of 4 patients had a serum M- component. Auto-immune hemolytic anemia occurred in 2 out of 4 patients. Histologic examinations revealed classical features of AILD-TL with more than 25% of large CD20+ cells with LMP-1 positivity in 2 cases. PCR analysis of tumoral lymph node showed a dominant T-cell clone in 2 cases, one of them also with a dominant B-cell clone. The two remaining cases had oligoclonal T-cell populations with polyclonal B-cell repertoire. A complete remission was achieved in 4 cases after 4 cycles and at the end of treatment for the 3 evaluable patients (treatment is still ongoing in one patient). One patient relapsed at 13 months with a low tumor burden and was treated with cyclophosphamide alone. At the present time, all the patients are alive without evolutive disease at 3, 20, 27 and 34 months. Conclusions : These results led us to consider that rituximab adjonction to CHOP could improve the prognosis of AILD-TL rich in large B cells. This combination warrants further evaluation in a larger phase II study. No significant financial relationships to disclose.
- Open Access
- 1 March 2004
- Published by Elsevier in Annals of Oncology
- Vol. 15 (3) , 504-510
Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cellnon-Hodgkin’s lymphoma: a single institution study
Background: Rituximab induces clinical response in advanced B-cell lymphoma and is efficient in removing circulating B-cell from peripheral blood. We therefore postulated that rituximab might be a useful in vivo purging agent before high-dose therapy in this setting. Patients and methods: Fourteen patients with relapsed follicular, marginal zone and mantle cell lymphomas (11, two and one cases, respectively) and a PCR-detectable molecular marker were treated first with rituximab, then a mobilization chemotherapeutic regimen, followed by high-dose therapy with peripheral blood stem cell transplantation. PCR analyses were performed in peripheral blood before rituximab and during follow-up, and in harvest. Results: Harvests were free of PCR-detectable molecular marker in nine of the 11 studied cases (82%). After high-dose therapy, clinical complete remission was obtained in 13 (93%) patients and molecular remission in 11 (79%). With a median follow-up of 3 years, the 14 transplanted patients were alive, 11 of them remaining in clinical complete remission and eight in molecular remission at last follow-up. Conclusion: Rituximab treatment followed by high dose therapy appears to be effective in achieving complete clinical and molecular response. In vivo harvest purging is predictive of prolonged clinical and molecular remission.
- 1 March 2004
- Published by Elsevier in Annals of Oncology
- Vol. 15 (3) , 504-510
Open AccessEfficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cellnon-Hodgkin’s lymphoma: a single institution study
Background: Rituximab induces clinical response in advanced B-cell lymphoma and is efficient in removing circulating B-cell from peripheral blood. We therefore postulated that rituximab might be a useful in vivo purging agent before high-dose therapy in this setting. Patients and methods: Fourteen patients with relapsed follicular, marginal zone and mantle cell lymphomas (11, two and one cases, respectively) and a PCR-detectable molecular marker were treated first with rituximab, then a mobilization chemotherapeutic regimen, followed by high-dose therapy with peripheral blood stem cell transplantation. PCR analyses were performed in peripheral blood before rituximab and during follow-up, and in harvest. Results: Harvests were free of PCR-detectable molecular marker in nine of the 11 studied cases (82%). After high-dose therapy, clinical complete remission was obtained in 13 (93%) patients and molecular remission in 11 (79%). With a median follow-up of 3 years, the 14 transplanted patients were alive, 11 of them remaining in clinical complete remission and eight in molecular remission at last follow-up. Conclusion: Rituximab treatment followed by high dose therapy appears to be effective in achieving complete clinical and molecular response. In vivo harvest purging is predictive of prolonged clinical and molecular remission.